Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf5438e78d5c9d3f7e0dc07c6b9c2dc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab14c7f70e81579e5f299eef6a5d0c07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7210d34690580da8fb07c26457e9fb6d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7e5c03e98273e433531399fe70daaf1 |
publicationDate |
2018-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018099045-A1 |
titleOfInvention |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
abstract |
Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10323093-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019112377-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10604575-B2 |
priorityDate |
2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |